H.C. Wainwright reiterates Buy on Tarsus stock, $88 target on acquisition

Tarsus Pharmaceuticals (TARS) received reaffirmation of a Buy rating with an $88 target (vs. $67.73), implying ~30% upside, supported by an acquisition that adds IRX-101 to its retina pipeline. In Q1 2026, Tarsus reported an EPS loss of -$0.16 (vs. -$0.30 expected) and revenue of $162M (vs. $153.12M forecast) alongside the iRenix Medical deal (~$75M total consideration, including $37.5M cash and $37.5M stock, plus up to $490M in milestones). Despite Culper Research disclosing a short position tied to the concentration in XDEMVY, analysts highlight strong balance sheet metrics (more cash than debt; current ratio 3.74) and expect Phase 3 IRX-101 initiation in 1H 2027 with topline results in 2028.

Analysis

TARS is still primarily a commercial story wearing a pipeline option. The market should treat the new asset as a long-dated call on retina adjacency, not as current NAV; with meaningful clinical milestones pushed into 2027-2028, most of the transaction value is narrative support rather than near-term earnings power. That matters because the stock’s multiple can expand on the perception of becoming a platform, but the cash flow bridge is still the same single-product engine.

The second-order read is balance-sheet optionality versus execution risk. If the core franchise keeps compounding, management can fund development without dilutive capital, which is what usually breaks fast-growing biotech rerates. But if prescription momentum slows or SG&A ramps faster than gross profit, the market will quickly reprice this back to a one-asset equity with a long-dated science lottery ticket attached.

For the broader software angle, the Starbucks example is a reminder that large enterprise buyers are getting more willing to internalize commodity workflows using AI. That is bearish for low-differentiation vertical SaaS and services stacks, but one customer is not enough to short a basket without proof of renewal pressure or cRPO decay. The contrarian point on TARS is that shorts may be over-fixated on concentration while underestimating how much a healthy balance sheet and real revenue growth can delay a de-rating event.

Key Decisions for Investors

• Long TARS on pullbacks over the next 1-3 months; target a 20-30% re-rating if XDEMVY growth and margins hold, with a clear stop if sequential script growth decelerates or guidance softens.
• Pair trade: long TARS / short XBI for the next 3-6 months to isolate idiosyncratic commercial execution from small-cap biotech beta; thesis breaks if broader biotech sentiment inflects sharply higher.
• Use strength in TARS to trim or sell covered calls into the 2027-2028 catalyst gap; the IRX-101 asset is too far out to justify chasing multiple expansion solely on pipeline optionality.
• No immediate trade in SBUX from the AI-tooling angle; place a watchlist on vertical SaaS exposed to large-chain customers (TOST, PAR, OLO) and only short on evidence of measurable vendor displacement or renewal pressure.